NIM Norwood Imm.

RNS Number:3443I
Norwood Immunology Ld
01 September 2006



                       NORWOOD IMMUNOLOGY LIMITED
                ('Norwood Immunology' or 'the Company')


          NORWOOD IMMUNOLOGY LIMITED ANNOUNCES SECURED LOAN FACILITY 
           AND CHANGES TO SIGNIFICANT SHAREHOLDINGS AND THE BOARD OF
                                 DIRECTORS


Norwood Immunology Limited ('the Company' or 'NIM') (AIM: NIM), the company
focussed on the rejuvenation of the immune system, announces that it has entered
into a secured facility agreement with Indus Opportunity Master Fund, Ltd 
('Indus') for A$1 million (the "Loan") to provide short term working capital
funding while the Company continues to seek new capital for the business, as
previously announced on 31 March 2006. The Loan is a drawdown facility for up to
A$1 million repayable within 12 months of the first drawing of funds and bearing
monthly interest.

The Company continues to maintain a careful control of its operational costs and
is seeking further funding to develop and commercialise its current technology.
As the outcome of this fundraising process is not currently certain, the Loan
provided by Indus, will in the interim fund the Company's short term working
capital requirements.

Further, the Company announces that Norwood Abbey Ltd ("NAL") has, on 1
September 2006, sold 31,395,346 ordinary shares it owns in NIM ("NIM Shares") to
Indus and related companies for a total consideration of US$7,102,363. The sale
by NAL represents 25.3% of NIM's current issued share capital. Following this
transaction, NAL has an interest in 62,219,654 NIM Shares, representing 50.2% of
NIM's current issued share capital.

Under the sale, Indus has purchased 31,395,346 NIM Shares representing 25.3% of
NIM's current issued share capital, which brings the total number of NIM Shares
held by Indus to 34,026,925, representing 27.5% of NIM's current issued share
capital.

As a consequence of the changing composition of NIM's shareholder base Ron
Lewis, Richard Zahn and Jeffrey Bell have resigned from the Board with immediate
effect, to make way for the future appointment of new non-executive Directors.
Announcements with respect to additions to the Board are expected to be made in
due course.

For further information please contact:

Richard Williams, Chief Executive Officer, Norwood Immunology Limited 
+44 (0)7860 295153

Lisa Baderoon, Mark Court, Mary-Jane Johnson, Buchanan Communications 
+44 (0)207 466 5000

Notes for editors:

Norwood Immunology has licensed its immunology intellectual property to TAP
Pharmaceutical Products Inc. for commercialization in the United States,
utilizing TAP's GnRH analogue, Lupron Depot(R) (leuprolide acetate for depot
suspension). This combined initiative is exploring the use of Lupron Depot in
regenerating the thymus gland and in turn "re-booting" the body's immune system,
enabling patients to better recover from life-threatening diseases.

TAP Pharmaceutical Products Inc., located in Lake Forest, IL., U.S.A., is a
joint venture between Abbott, headquartered in Abbott Park, IL., U.S.A ., and
Takeda Pharmaceutical Company Limited of Osaka, Japan. TAP currently markets
Lupron Depot and Prevacid(R) (lansoprazole). For more information about TAP and
its products, please visit the company's web site at www.tap.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

MSCIIFFEAVILIIR

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Giu 2023 a Giu 2024